Fibrocell Science, Inc. Extends Patent Protection for LAVIV® (azficel-T) Through 2031
7/2/2013 8:34:41 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), creator of the first FDA-approved autologous cellular product, LAVIV® (azficel-T) for aesthetics, announced today that the United States Patent and Trademark Office (USPTO) has awarded a patent to the Company which covers azficel-T fibroblast suspension, extending the patent exclusivity in the United States until 2031.
Help employers find you! Check out all the jobs and post your resume.
comments powered by